Compounded GLP-1s in 2026: Legal Status, FDA Actions Explained

Drug compounding is the practice of a licensed pharmacy preparing a medication itself — combining, mixing, or altering ingredients to produce a specific product — rather than dispensing a factory-made version approved by the FDA. Traditional compounding (under section 503A of the federal Food, Drug, and Cosmetic Act) exists for individual prescriptions a commercial product cannot serve; outsourcing facilities (503B) make larger batches under different rules. Neither path normally permits copying an FDA-approved drug that is readily available.

"Compounded GLP-1" refers to copies of the branded injectables — semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) — prepared by compounders as the same active ingredient, and dispensed largely through the online telehealth channel that grew up around the shortage permission. The critical fact about these products is what they are not: they are not FDA-approved products. No FDA review established the identity, purity, potency, or manufacturing controls of any specific compounded copy. During the shortage era that was a tolerated trade-off; the entire legal question since has been whether that tolerance survives the shortage's end.

The legal foundation was the FDA's drug shortage list. When the FDA formally determines that an approved drug is in shortage, federal law lets compounders prepare copies of it — a flexibility intended to keep patients supplied when the approved manufacturer cannot. During the multi-year GLP-1 supply crunch, demand for semaglutide and tirzepatide outran manufacturing capacity, the injectables spent extended periods on the shortage list, and a large telehealth-compounding market grew up almost overnight around that permission.

The arrangement worked because it was temporary by construction. The compounding flexibility is tied to the shortage determination itself: it exists while the shortage exists, plus whatever enforcement-discretion grace period the FDA grants so the market can wind down. That is the context everything in 2025 and 2026 must be read against — when the shortage ended, the shortage-based permission to compound copies of these drugs ended with it, subject to the wind-down grace periods the FDA granted.

The FDA determined that the shortages of the branded GLP-1 injectables were resolved — tirzepatide first, semaglutide later. Tirzepatide came off the FDA's drug shortage list on October 2, 2024, and the FDA issued a declaratory order on the determination on December 19, 2024; the corresponding semaglutide order followed on February 21, 2025. With those determinations, the shortage-era footing for compounding copies of these drugs disappeared. The FDA gave the market bounded grace periods to exhaust existing supply and transition patients, and those grace periods expired during 2025.

After expiry, the baseline rule reasserted itself: compounding copies of commercially available, FDA-approved drugs is not permitted under the shortage flexibility, because there is no shortage to justify it. That is a statement about regulatory status, not an instant physical disappearance of the market — a distinction the next section makes concrete. The practical takeaway from 2025 is that the question "is compounded semaglutide legal?" flipped from "yes, under a documented FDA flexibility" to "not under the rule that authorized it," while the products themselves remained easy to find.

Through 2026 the FDA has moved from policy statements to enforcement. In March 2026 alone it issued roughly 30 warning letters to telehealth companies over compounded GLP-1 marketing and sales — letters that put recipients on the public record and typically demand corrective action. The campaign targets the sellers: claims, promotion, and distribution patterns around compounded copies of drugs that are no longer in shortage.

Yet the market persists. US News reported in July 2026 that compounded versions of semaglutide and tirzepatide remained widely available. That gap — escalating enforcement alongside continued wide availability — is the defining shape of 2026: warning letters are the FDA's chosen instrument, enforcement is uneven and case-by-case, and a product being easy to purchase says nothing about its regulatory status. Readers should hold those two facts together rather than choosing between them, and treat any seller's assurance of legality as a claim to verify, not a fact.

On October 14, 2026, an FDA submission titled "Interim Access Policy for Compounding Using Certain Peptides" appeared on the OIRA review dashboard at reginfo.gov, logged at the Notice stage — meaning it is under White House review before the public sees the actual text. On October 15, 2026, Reuters reported — citing the OMB filing and two people familiar with the matter — that the interim policy would let pharmacies compound certain popular peptides, including BPC-157.

This is a real and significant story, but it is not the GLP-1 story, and conflating the two is the most common error in current coverage. The interim-access policy belongs to a different regulatory track: per Reuters's reporting on the filing, it concerns which bulk substances 503A compounding pharmacies may use — the same track as the Pharmacy Compounding Advisory Committee's July 23, 2026 votes to recommend adding six of seven peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax; DSIP was rejected) to the bulk-substances list, votes cast against the FDA staff's own recommendation in docket FDA-2025-N-6895. That track governs peptides like BPC-157, which are not approved drugs at all. It does not restore the shortage-era permission to compound copies of semaglutide or tirzepatide, which are approved drugs that are no longer in shortage. A future in which pharmacies may lawfully compound BPC-157 is fully consistent with compounded GLP-1s remaining outside the rules — which is exactly why this page keeps the tracks separate. Two caveats on the October 14 entry itself: the policy's actual text had not been published as of October 16, 2026, and an OIRA filing changes no current compounding permission by itself.

The unresolved questions are practical. Will the interim access policy survive White House review, what will its final text cover, and how will the FDA reconcile it with its own staff's position after the PCAC votes? How far will the warning-letter campaign go — more letters, import alerts, or joint actions with other agencies? And what happens to the patients who built regimens around compounded copies if supply actually contracts? None of these has an answer yet, and this page will say so plainly rather than predicting.

The consumer-risk layer is independent of the policy calendar. A compounded injectable has, by definition, not been through FDA review as a product: identity, purity, sterility, and potency depend on the individual compounder's practices rather than on an approved manufacturing chain. Anyone weighing claims about these products should verify against the official record: the FDA's public warning-letter archive, its drug shortage database, and the OIRA dashboard at reginfo.gov. Official records move slower than headlines and are always the better citation.

PeptaHub updates this page when the underlying facts move: new FDA warning letters or enforcement actions touching compounded GLP-1s, changes to the FDA drug shortage database, action on the interim access policy at OMB or upon publication of its text, and material shifts in availability documented by credible reporting. The last-updated date at the top moves with every material revision, and each update keeps the two regulatory tracks in their own sections — the page's core value is that a reader can always tell which law is being discussed.

This page is educational. It recommends no compounder, no telehealth service, and no seller; it publishes no prices as advice and gives no dosing, sourcing, or purchasing guidance of any kind — for research compounds or for prescription drugs. Nothing here is legal advice either: regulatory status and enforcement posture are described as matters of public record, and anyone with a personal stake should rely on the FDA's own publications, licensed pharmacists, and qualified counsel.

This topic is YMYL at its most concentrated: regulated health products, an enforcement picture that changes month to month, and a commercial ecosystem with strong incentives to blur the lines. PeptaHub's role is to structure the public record accurately and keep it current — not to steer any purchasing decision.